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Abstract
The coordinate regulation of HLA class II (HLA-II) is controlled by the class II transactivator, CIITA, and is crucial for the
development of anti-tumor immunity. HLA-II in breast carcinoma is associated with increased IFN-c levels, reduced
expression of the estrogen receptor (ER) and reduced age at diagnosis. Here, we tested the hypothesis that estradiol (E2)
and ERa signaling contribute to the regulation of IFN-c inducible HLA-II in breast cancer cells. Using a panel of established
ER2 and ER+ breast cancer cell lines, we showed that E2 attenuated HLA-DR in two ER
+ lines (MCF-7 and BT-474), but not in
T47D, while it augmented expression in ER2 lines, SK-BR-3 and MDA-MB-231. To further study the mechanism(s), we used
paired transfectants: ERa+ MC2 (MDA-MB-231 c10A transfected with the wild type ERa gene) and ERa2 VC5 (MDA-MB-231
c10A transfected with the empty vector), treated or not with E2 and IFN-c. HLA-II and CIITA were severely reduced in MC2
compared to VC5 and were further exacerbated by E2 treatment. Reduced expression occurred at the level of the IFN-c
inducible CIITA promoter IV. The anti-estrogen ICI 182,780 and gene silencing with ESR1 siRNA reversed the E2 inhibitory
effects, signifying an antagonistic role for activated ERa on CIITA pIV activity. Moreover, STAT1 signaling, necessary for CIITA
pIV activation, and selected STAT1 regulated genes were variably downregulated by E2 in transfected and endogenous ERa
positive breast cancer cells, whereas STAT1 signaling was noticeably augmented in ERa2 breast cancer cells. Collectively,
these results imply immune escape mechanisms in ERa+ breast cancer may be facilitated through an ERa suppressive
mechanism on IFN-c signaling.
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Introduction
Antigen presentation by major histocompatibility complex
(MHC) class II molecules (MHC-II), known as HLA-II (HLA-
DR, -DP, -DQ) in humans and co-chaperones HLA-DM and the
invariant chain (Ii) are important for the development of adaptive
immune responses including anti-tumor immunity [1–4]. Typi-
cally, HLA-II expression is limited to professional antigen
presenting cells (pAPC), but is induced by IFN-c on most cell
types including those derived from cancer [5,6]. HLA-DR positive
tumor cells have been described in several malignancies, such as
melanoma [7], colon [8,9] and breast [10–12], but the underlying
mechanisms are likely diverse. The number of HLA-II positive
tumor cells in breast cancer is directly associated with tumor
infiltrating immune cells and levels of IFN-c [12–14], but other
cytokines, hormones, growth factors and oncogenes are also
implicated in regulating HLA-II expression [15–20].
HLA-II expression is controlled at the transcription level by a
highly conserved regulatory module, located in the promoter of
genes encoding the a- and b-chains of all HLA-II molecules and in
the gene encoding the Ii co-chaperone [21–26]. This regulatory
module forms a platform for the class II transactivator (CIITA), a
non-DNA binding protein, which acts as a transcriptional
integrator by connecting transcription factors, bound to the
MHC-II promoter with components of the general transcriptional
machinery [23,27–30]. The central role of CIITA is evident from
lack of constitutive or IFN-c inducible HLA-II in bare lymphocyte
syndrome [31,32].
CIITA expression is controlled by three distinct promoters:
promoter I (pI) for constitutive expression in dendritic cells;
promoter III (pIII), for constitutive expression in B cells; promoter
IV (pIV) for IFN-c inducible expression [21,26,33]. This promoter
system is crucial for controlling CIITA messenger RNA (mRNA)
and protein levels, and they, in turn, regulate HLA-II expression.
The molecular regulation of CIITA pIV is intricately linked to the
classical IFN-c signaling pathway. IFN-c, binds to IFN-c receptors
(IFNGR) on the cell surface, resulting in autophosphorylation of
Janus kinase 2 (JAK2) and JAK1, followed by phosphorylation,
dimerization and nuclear translocation of signal transducer and
activator of transcription 1 (STAT1) [34,35]. Phosphorylated
STAT1 (pSTAT1) binds to IFN-activated sites (GAS) in the
promoter of target genes including the IFN-regulatory factor 1
(IRF1), thus stimulating its expression. IRF1 binds cooperatively
with IRF2 to its associated IRF element (IRF-E) in CIITA pIV,
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and concomitant pSTAT1 binding to GAS in CIITA pIV results
in transcriptional activation of CIITA [33,36]. Moreover,
signaling pathways such as mitogen activated protein kinases
(MAPK) and PI3K/Akt that are frequently activated in breast
cancer cells [37] modulate expression of IRF1 and STAT1 [38–
40], further impacting the levels of IFN-c inducible CIITA and
subsequent HLA-II expression on tumor cells.
Previously, we showed that HLA-II (HLA-DR, HLA-DM and
Ii) was discordantly expressed on tumor cells in human breast
cancer tissues [12]. Furthermore, tumor cell expression of HLA-
DR and Ii, but not HLA-DM, correlated with reduced expression
of estrogen receptors (ER) and reduced age at diagnosis.
Importantly, tumors with coordinate expression of HLA-DR, Ii
and HLA-DM had the highest IFN-c mRNA levels and correlated
with increased patient survival [12]. Undoubtedly, the mecha-
nisms governing tumor cell expression of HLA-II in breast
carcinoma are likely multifaceted, involving IFN-c secreted by
infiltrating immune cells [12], circulating and tumor-associated
estrogens [41] and activation of growth factor and hormone
receptor pathways in the tumor cells [42,43]. Estradiol and anti-
estrogens, tamoxifen and fulvestrant or ICI 180,720 (ICI), were
shown to modulate IFN-c inducible MHC-II in various cell types
[17,19,44,45] through mechanisms not involving ligand activation
of the estrogen receptor (ER) pathway.
In this study, using established human ER2 and ER+ breast
cancer cell lines (BCCL) and an ERa-transfected BCCL, we
investigated the specific and combined effects of estradiol (E2) and
ERa on HLA-II regulation. We found IFN-c inducible HLA-II
expression was modulated by E2-ER activation at the level of the
CIITA pIV. Furthermore, E2-treatment of ERa
+ BCCL and
ERa2 BCCL differentially affected various components of the
IFN-c signaling pathway that are required for transactivation of
CIITA pIV.
Results
Estradiol differentially modulates HLA-DR expression in
breast cancer cell lines
Stemming from our previous finding that HLA-II expression in
breast carcinoma tissues correlates with increased IFN-c mRNA,
reduced age at diagnosis and reduced ER levels [12] we
questioned whether E2, in the absence or presence of its cognate
receptor ERa, modulates HLA-DR expression in established ER2
and ER+ BCCL, treated or not with IFN-c for 96 hours. Analysis
of ER2 BCCL using flow cytometry (Figure 1A & 1B) revealed low
basal expression of HLA-DR in MDA-MB-231, but not in SK-
BR-3 while IFN-c induced strong expression in both cell lines. E2-
treatment augmented IFN-c inducible HLA-DR, although this
was significant for only SK-BR-3 (Figure 1B). These results,
confirmed by Western blot analysis of cell lysates (Figure 1C &
1D), suggest E2 may modulate HLA-DR expression in ER
2 breast
cancer through an ERa independent mechanism [46].
Since the least HLA-DR in human breast carcinoma tissues
occurred in ER+ tumors [12] we hypothesized that E2-activation
of the ERa pathway inhibits HLA-DR expression. Analysis of ER+
BCCL, treated as described above, revealed a variable pattern of
IFN-c inducible HLA-DR expression with amounts that were
barely detectable, moderate and abundant in BT-474, MCF-7,
and T47D, respectively (Figure 1E & 1F). Constitutive HLA-DR
was detected at the cell surface in only T47D (Figure 1E).
Furthermore, E2 treatment significantly reduced HLA-DR in
MCF-7 and BT-474, but not in T47D (Figure 1E). Similar results
were obtained from Western blot analysis of cell lysates (Figure 1G
& 1H). Notably, ERa levels were not altered by IFN-c but E2
treatment increased the amount in the nucleus, indicating ligand
activation of the ERa pathway (Figure. 1G). Taken together these
data suggest that E2-inhibition of HLA-II expression in ERa
+
BCCL is mediated through activation of ligand-dependent ERa
pathway.
Transfection of ESR1 in an ER- cell line diminishes IFN-c
inducible HLA-II proteins
To further explore the role of ERa on IFN-c inducible HLA-
DR, we used two stably transfected cell lines, derived from MDA-
MB-231 clone 10A [47,48]: MC2 expresses wild type ERa and
VC5 expresses the empty vector. Since MDA-MB-231 clone 10A
was selected for negative expression of ERa and ERb [47], the
transfected pair is a suitable model to assess ERa mediated effects
on HLA-II without interference from other ERs including GPR30,
reported to be deficient in MDA-MB-231 [48,49]. The cells,
treated and analyzed for HLA-DR expression as described above,
revealed significantly reduced cell surface HLA-DR in MC2, as
compared to VC5 and MDA-MB-231 clone 10A (Figure 2A &
2B). Moreover, E2-treatment greatly diminished HLA-DR in
MC2 but not in VC5 and MDA-MB-231 clone 10A. These results
were confirmed by Western blot analysis of cell extracts
(Figure 2C). Again, HLA-DR protein in the ERa+ MC2 was
severely reduced and exacerbated by E2, whereas MDA-MB-231
clone10A and VC5 expressed abundant HLA-DR in the presence
and absence of E2. As the only known difference between MC2
and VC5 is the expression of ERa, these results further implicate
ERa in negatively regulating HLA-DR expression.
Although HLA-II genes are coordinately regulated [25], we
found most breast cancer lesions with HLA-DR+ tumor cells do
not have detectable HLA-DM expression [12]. We reasoned that
if ERa and its activation by E2 coordinately down regulates HLA-
II, then blocking ER signaling with ICI, a selective anti-estrogen
that degrades ER, should reverse the inhibition. To test this
hypothesis, MC2 and VC5 were pretreated with 1026 M ICI in
the presence or absence of 1029 M E2. Following stimulation with
IFN-c for 96 hours, HLA-DR, -DM and Ii were analyzed by flow
cytometry and Western blot. HLA-DR, -DM and Ii expression
levels were significantly reduced in MC2 compared to VC5
(Figure 3A–3C), while E2-treatment further diminished HLA-II
expression in MC2, but not in VC5. Although ICI-treatment,
alone or with E2, did not restore HLA-II in MC2 to VC5 levels, it
clearly reversed the E2-inhibitory effect on HLA-II expression.
Western blot analysis (Figure 3D–3G) and immunocytochemistry
(data not shown) confirmed the reduced expression of HLA-DR, -
DM and Ii in MC2 and the involvement of ERa signaling in the
inhibitory effect of E2 on HLA-II expression.
Activation of the ERa signaling pathway impedes CIITA
expression
Since HLA-II expression is coordinately regulated by CIITA,
we predicted that ERa interfered with CIITA expression in ERa-
expressing MC2. MC2 and VC5 were pretreated with E2 and/or
ICI, as described above, followed by addition of IFN-c for
24 hours. Western blot analysis of nuclear and cytoplasmic
extracts showed inducible CIITA expression in MC2 was about
70% of VC5 levels (Figure 4A & 4B). E2-treatment further reduced
CIITA in MC2 while increasing the amount of nuclear ERa; in
contrast, ICI reversed the inhibitory effect of E2 on CIITA
expression, coincident with ICI-mediated reduced ER levels
(Fig 4A Lanes 7 and 8). These results indicated that E2 inhibits
HLA-II expression by downregulating CIITA expression.
HLA Class II Expression in ERa Breast Cancer
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To further determine the inhibitory effect of E2 on CTIIA gene
expression, VC5 and MC2 cells were pretreated with E2 and/or
ICI for 1 hour and then stimulated with and without IFN-c for
4 hours, an optimal time for CIITA mRNA expression [50].
CIITA transcription was induced in both VC5 and MC2, but the
induction of CIITA mRNA in MC2 was about half in VC5
(Figure 4C). E2 further decreased CIITA mRNA in MC2, while
ICI reversed the E2-mediated effect on CIITA.
To confirm the above results, we silenced the ERa transgene in
MC2 using ESR1 siRNA and then treated with E2 or vehicle
Figure 1. E2 differentially modulates inducible HLA-DR expression in ERa
+ and ERa2 breast cancer cell lines. MDA-MB-231, SK-BR-3,
MCF-7, BT-474, and T47D were cultured in E2-depleted media, treated with vehicle (ethanol) or E2 (10
29 M) and stimulated or not with IFN-c (100 U/
ml) for 96 hours. (A & E) HLA-DR cell surface expression (L243) was analyzed by flow cytometry: grey line, isotype control; black line, constitutive
expression; shaded histogram, IFN-c induced expression. (B & F) Bar graphs represent the MFI (mean florescence intensity) 6 SEM for HLA-DR
expression of three independent experiments. (C & G) Western blot analysis was performed on cytoplasmic and nuclear extracts for ERa expression
(HC-20) and on cytoplasmic extracts for HLA-DRa (TAL 1B5). Protein loading controls included a-tubulin (B-7) and P84 (5E10) for cytoplasmic and
nuclear proteins, respectively. (D & H) Bar graphs show the ratio of band intensity for HLA-DRa, normalized to the a-tubulin band intensity and
represent the mean 6 SEM of three independent experiments (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0087377.g001
HLA Class II Expression in ERa Breast Cancer
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control followed by IFN-c stimulation for 24 hours. VC5, treated
in the same way, was used as a control. Western blot analysis of
cell lysates showed ERa was greatly reduced in MC2 transfected
with ESR1 siRNA, but not with scrambled siRNA (Figure 5A).
Similar to the ICI-mediated effects, ESR1 siRNA clearly reversed
the E2-mediated inhibition observed in the scrambled siRNA
transfectants. E2 increased CIITA in the ER
2 VC5, whether
transfected with scrambled or ESR1 siRNA. Analysis of CIITA
transcripts using real time PCR on siRNA-treated cells (Figure 5B),
revealed equivalent levels of CIITA transcripts in ESR1 and
scrambled siRNA transfectants; again, ESR1-siRNA abolished the
inhibitory effect of E2 on constitutive and induced CIITA
transcripts. These results suggest a mechanism whereby E2-
activated ER interferes with CIITA transcription induced by IFN-
c in breast cancer cells.
E2 activated ERa inhibits CIITA promoter IV activity
Since IFN-c inducible HLA-II expression requires activation of
CIITA pIV [33], we hypothesized that E2 activation of ERa
interferes with CIITA pIV activity. We transfected VC5 and MC2
with a CIITA pIV luciferase construct and treated the cells with E2
and/or ICI, followed by stimulation or not with IFN-c for
12 hours. E2-treatment further reduced both basal and IFN-c
induced CIITA pIV activity in MC2, while ICI reversed the
inhibitory effect of E2 in MC2 cells (Figure 6). Treatment with ICI
and/or E2 did not significantly affect constitutive or IFN-c
inducible CIITA pIV activity in VC5.
To determine whether E2 directly regulates CIITA pIV activity,
we searched for presence of ERE sites using three different
computer software programs (http://tfbind.hgc.jp/, http://
alggen.1si.upc.es/ and http://www.cbrc.jp/index.eng.html) and
identified four putative ERE sites in CIITA pIV (Figure 7A, bold
letters in boxes). Sites 1 to 3 are upstream of the STAT1 and IRF1
binding sites. Site 4 is downstream of these sites and precedes the
start codon. To determine if either of these sites serves as an ERa
repressor of CIITA transcription, three deletion mutant constructs
(Site 1/2 deletion mutant, Site 3/4 deletion mutant and Site 1–4
deletion mutant) were created (Figure 7A, open boxes). VC5 and
MC2, transfected with one of the mutant CIITA pIV constructs,
were pretreated with E2 or vehicle control and then stimulated
with IFN-c for 12 hours, followed by measurement of luciferase
activity (Figure 7B, left panel). All three deletion constructs
demonstrated significantly reduced IFN-c stimulated CIITA pIV
activity in E2-treated MC2, similar to that observed in MC2
transfected with the wild type CIITA pIV plasmid. By comparison
CIITA pIV activity was similar in E2 or vehicle treated VC5 cells
whether transfected with wild type or deletion constructs.
Intriguingly, constructs Del 3 & 4 and Del 1–4 resulted in
dramatic and significant loss of CIITA pIV activity in both cell
lines, suggesting there may be other or overlapping sites in CIITA
pIV that interact with currently unknown transcription factors for
a fully active promoter. Alternatively, the deletion of these sites
may have led to the creation of a novel site that has an inhibitory
effect on CIITA pIV activity. Importantly, these results do not
support the hypothesis that diminished CIITA pIV activity in
MC2 treated with E2 occurs via ERE sites in the proximal region
of CIITA pIV.
E2-ERa interferes with STAT1 signaling in ERa transfected
MC2 cells
To explore whether STAT1 signaling, necessary for activation
of CIITA pIV, is adversely affected by ERa activation, we
transfected the 8 X GAS luciferase plasmid in VC5 and MC2,
followed by treatment, or not, with E2 and/or IFN-c for 6 hours.
Compared to VC5, STAT1 signally was clearly reduced in MC2
(Figure 8A & 8B); moreover, E2 significantly reduced basal and
induced GAS promoter activity by about 44% and 40%,
respectively, in MC2 (Figure 8B). Although E2 increased basal
GAS promoter activity by about 28% in VC5, this was not
significant; E2 had no effect on induced activity (Figure 8A).
To test whether reduced GAS activity in MC2 was the result of
reduced pSTAT1, we performed Western blot analysis on lysates
from cells treated or not with IFN-c for 15 minutes. As shown in
Figure 8C, total STAT1 and pSTAT1 at tyrosine (Y) 701 and
serine (S) 727 were reduced in MC2, compared to VC5. Similar
Figure 2. IFN-c inducible HLA-DR is down regulated in the ERa+
transfected breast cancer cell line, MC2. MDA-MB-231 clone 10A
(MDA-231 c10A), VC5 (MDA-231 c10A, transfected with the empty
plasmid vector) and MC2 (MDA-231 c10A, transfected with wild type
ESR1) were cultured in E2-depleted medium and stimulated or not with
IFN-c (100 U/ml) for 96 hours. (A) HLA-DR cell surface expression (L243)
was analyzed by flow cytometry: grey line, isotype control; black line,
constitutive expression; shaded histogram, IFN-c induced expression.
(B) Bar graphs represent the MFI 6 SEM for HLA-DR expression of three
independent experiments (***p,0.001). (C) Western blot analysis was
performed on whole cell lysates for HLA-DRa (TAL 1B5) and ERa (HC-
20).
doi:10.1371/journal.pone.0087377.g002
HLA Class II Expression in ERa Breast Cancer
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results were observed in an experiment in which cells were also
treated with E2 for 4 hours, followed by IFN-c treatment for 15
minutes; moreover, E2 did not alter levels of phosphorylated or
total STAT1 in MC2 or in VC5 (Figure 8D). We next examined
IRF1 expression, also essential for CIITA pIV activation, in MC2
and VC5, treated with E2 and stimulated with IFN-c for 96 hours
(Figure 8E). We found IRF1 levels were significantly decreased in
MC2, compared to VC5, that E2-treatment had only a trivial
effect on IRF1 in MC2, whereas it significantly increased the levels
in VC5. Collectively, these results show that ectopic expression of
ERa and, moreover, its activation by E2 attenuates STAT1
signaling, however, E2 has only a marginal inhibitory effect on
IRF1 levels in MC2. These findings imply that attenuation of
CIITA pIV and subsequent reduced HLA-II expression in ERa
positive breast cancer may be due to defects in STAT1 regulation.
E2 differentially affects IFN-c signaling in established
ERa+ and ERa2 breast cancer cells
To ensure that attenuated STAT1 signaling in MC2 was not
merely a peculiarity of the transfected model, we further analyzed
Figure 3. Coordinate downregulation of IFN-c inducible HLA-II expression by E2 is reversed by ICI-mediated degradation of ERa in
MC2 cells. VC5 and MC2 cells were cultured in E2-depleted media, treated with vehicle (ethanol), E2 (10
29 M) or/and ICI (1026 M) followed by
stimulation with IFN-c (100 U/ml) for 96 hours. HLA-II expression was analyzed by surface flow cytometry using (A) anti-DR, (L243), and intracellular
flow cytometry using (B) anti-DM (Map.DM1) and (C) anti-Ii (LN2). Bar graphs represent the MFI 6 SEM of three independent experiments. (*p,0.05,
**p,0.01). (D) Western blot analysis was performed on whole cell extracts using for HLA-DRa (TAL 1B5), HLA-DM (TAL18.1) and Ii (LN2); GAPDH
(Ab8245) is the protein loading control. Bar graphs show the ratio of band intensities, normalized to GAPDH band intensities and represent the mean
6 SEM ratio of three independent experiments: (E) HLA-DRa/GAPDH (F) HLA-DM/GAPDH, and (G) Ii/GAPDH (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0087377.g003
HLA Class II Expression in ERa Breast Cancer
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GAS promoter activity in endogenously ERa+ BCCL: MCF-7,
BT-474 and T47D and ERa2 BCCL: MDA-MB-231 and SK-
BR-3. E2 significantly decreased IFN-c induced GAS activity in
MCF-7 and BT-474, (Figure 9A & 9B) but not in T47D
(Figure 9C). To further confirm the inhibitory effect of E2 on
IFN-c signaling in BCCLs, other than HLA-DR (Figure 1), we
conducted Western blot analysis of IFN-c inducible proteins.
These included STAT1, IRF1, IRF9, a member of the IRF family
of transcription factors that is not implicated in CIITA expression
[51], and gamma-interferon-inducible lysosomal thiol reductase
(GILT), a STAT1 regulated but CIITA-independent protein, that
is important for antigen processing [52] Basal and IFN-c inducible
STAT1 levels were not substantially altered by E2 in either cell line
(Figure 9D–9F); however, STAT1 regulated proteins, IRF1, IRF9
and GILT were differentially modulated in E2-treated MCF-7 and
BT-474 (Fig 9D & 9E).
In contrast to the E2-inhibitory effect on GAS promoter activity
in the ERa+ lines, E2 noticeably enhanced GAS promoter activity
in ERa2 BCCL, MDA-MB-231 and SK-BR-3 (Figure 9G & 9H).
Furthermore, E2-treatment augmented expression of IRF1 and
GILT in MDA-MB-231 cells, and of STAT1 in SK-BR-3
(Figure 9I & 9J). Taken together, the results suggest that E2
differentially modulates the IFN-c and HLA-II pathways in ERa+
and ERa2 BCCL.
Discussion
We previously reported the frequency of HLA-II positive tumor
cells in ER+ breast carcinomas is decreased, compared to ER2
tumors from younger women [12]. As estrogen levels are high in
breast carcinoma tissues, irrespective of age and menopausal
status[41], we hypothesized a negative role for estrogen-activated
ERa in HLA-II regulation in breast cancer cells. Herein, we
provided experimental evidence that ERa and E2-activated ERa
attenuate HLA-II expression in BCCL. Using paired ERa (MC2)
and vector (VC5) transfected MDA-MB-231 clone 10A cells we
showed: i) E2-treatment coordinately decreased IFN-c inducible
HLA-II and CIITA in ERa+ MC2 but not in ERa2 VC5; ii)
reduction of ERa by ICI or siRNA reversed the E2-inhibitory
effect on HLA-II expression, CIITA pIV activity and transcrip-
Figure 4. E2-ERa signaling down regulates CIITA protein and mRNA expression in ER
+ BCCL. VC5 and MC2 cells were cultured in
E2-depleted media, treated with vehicle (ethanol), E2 (10
29 M) or/and ICI (1026 M) and stimulated or not with IFN-c (100 U/ml) for 24 and 4 hours, for
CIITA protein and mRNA expression, respectively. (A) Western blot analysis was performed on cytoplasmic and nuclear extracts for CIITA (antiserum
#21) and ERa (HC-20). (B) Cytoplasmic CIITA and nuclear CIITA were normalized to GAPDH and P84 respectively; bar graphs represent the mean 6
SEM ratio of three independent experiments (**p,0.01). (C) CIITA mRNA was relatively quantified by real time PCR using Taqman gene expression
assay. GAPDH was used as an endogenous control and the data were expressed relative to a control B cell line (RAJI). Bar graphs represent the mean
6 SEM of three replicate assays (**p,0.01).
doi:10.1371/journal.pone.0087377.g004
HLA Class II Expression in ERa Breast Cancer
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tional activation of CIITA in MC2; iii) E2-activated ERa adversely
affected IFN-c induced transcription as shown by GAS reporter
assay and expression levels of IFN-c inducible proteins. Impor-
tantly, similar results were observed in the ERa+ BCCL, MCF-7
and BT-474, in which GAS activity, STAT1 regulated genes and
HLA-DR were down regulated by E2; by contrast, E2 augmented
GAS activity and expression of STAT1 regulated genes in the
ERa2 BCCL, MDA-MB-231 and SK-BR-3.
Overall our data support a negative role for E2-ERa signaling in
the regulation of HLA-II in breast cancer cells, but cell-specific
differences are evident. For example, E2 treatment attenuated
HLA-DR in MCF-7 and BT-474, but not in T47D. This finding is
compatible with an older study in which BCCL, cultured in E2-
sufficient medium, exhibited a hierarchy of IFN-c inducible HLA-
DR levels with T47D.MCF-7.BT-474 [6]. Differential HLA-II
in these cells is not surprising, given that ER+ BCCL, although
expressing many of the same genes associated with a luminal
subtype, will differ in expression of many other genes [53], which
may or may not be regulated by E2. Multiple factors including the
ratio and localization of ERa and ERb receptors, levels of
coactivators and corepressors, cell surface receptors such as
GPR30 and EGFR and cross-talk with other signaling pathways
determine which genes are up or down regulated [54]. E2-
activated ERb inhibits recruitment of ERa to ERE in target genes,
thus, suppressing ERa regulated gene expression [55]. Further-
more, activation of the ERb2 isoform results in ERb2/ERa
heterodimers that are targeted for proteasomal degradation [56].
It is noteworthy, then, that E2 increases ERb in T47D but not in
MCF-7 or BT-474 [57] and the ER b:a ratio in T47D is reported
to be greater than in MCF-7[53,58] thus, suggesting that cell-
specific differences in ER subtypes and other receptors may
underlie differential HLA expression in breast cancer.
The most convincing evidence that activated ERa modulates
HLA-II and CIITA expression came from our experiments using
the transfected ERa+ line, MC2. Since MC2 and its ERa2 vector
control, VC5, are derived from MDA-MB-231 clone 10A, which
is negative for both ERa and ERb[47], it should be a valid model
to directly assess the effect of activated ERa on the HLA-II
pathway. Our finding, that E2 attenuation of HLA-II and CIITA
in MC2 could be reversed by knockdown of ERa in MC2 with ICI
(Figures 3D and 4A) or siRNA (Figures 5A), provides compelling
evidence that the classical ERa signaling pathway interferes with
CIITA regulation. However, we were puzzled that even without
adding E2, HLA-II and CIITA were reduced in MC2 and that
knockdown of ERa by ICI and siRNA did not restore CIITA
activity in MC2 to VC5 levels. Although we used phenol red free
medium and E2-depleted FBS, there might still be a minimum
level of E2 in the culture medium, which is sufficient to activate
ERa and suppress CIITA activity. Furthermore, the incomplete
depletion of ERa by ICI or siRNA (Figures 3D, 4A & 5A), may
also explain why HLA-II and CIITA expression were not
completely restored.
Identification of putative ERE binding sites in the proximal
region of CIITA pIV (Figure 7A) led us to explore a direct role for
Figure 5. Silencing ERa with ESR1 siRNA reversed the
inhibitory effect of E2 on CIITA expression. (A) ERa was silenced
(ESR1 siRNA) or not (scrambled siRNA) in MC2; VC5 served as an ERa
negative cell control. Cells were treated with vehicle (ethanol) or E2
(1029 M) and stimulated or not with IFN-c (100 U/ml) for 24 hours.
Nuclear lysates were prepared and probed for CIITA (anti-serum #21),
ERa (HC-20), and p84. Each figure represents one of three individual
experiments. (B) ESR1 siRNA and scrambled siRNA transfected MC2 cells
were treated with either vehicle (ethanol) or E2 (10
29 M) followed by
stimulation with or without IFN-c (100 U/ml) for 4 hours and CIITA
mRNA was relatively quantified by real time PCR using Taqman gene
expression assay. GAPDH was used as an endogenous control and the
data were expressed relative to a control B cell line (RAJI). Bar graphs
represent the mean 6 SEM of three replicate assays (*** p,0.001).
doi:10.1371/journal.pone.0087377.g005
Figure 6. E2-ERa signaling pathway interferes with CIITA pIV
activity in MC2. VC5 and MC2 cells were cultured in E2-depleted
media followed by transfection with CIITA pIV luciferase constructs. On
the following day, cells were treated with vehicle (ethanol), E2 (10
29 M)
and/or ICI (1026 M), and stimulated or not with IFN-c (100 U/ml) for
12 hours. Data are expressed as fold induction over the PGL2 Basic
empty plasmid after controlling for transfection efficiency using cells
dual transfected with GFP (Green Florescent Protein). The effect of ERa
on the transcription activation of CIITA PIV was determined from
relative luciferase activities in transfected MC2. Error bars represent the
mean 6 SEM of three independent experiments (**p,0.01).
doi:10.1371/journal.pone.0087377.g006
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Figure 7. Mutation of putative ERE sites in CIITA pIV does not enhance CIITA pIV activation in MC2. (A) CIITA pIV nucleotide sequence
from 2346 to +50 with the GAS and IRF1 binding sites (shaded hexagon) and the predicted ERE (clear rectangles) were identified using online
transcription factor prediction software, (http://tfbind.hgc.jp/, http://alggen.lsi.upc.es/ and http://www.cbrc.jp/index.eng.html). Site directed
mutagenesis was used to perform deletion of the predicted ERE. (B) VC5 and MC2 were transfected with CIITA pIV constructs, then treated with
vehicle (ethanol) or E2 (10
29 M) and stimulated with IFN-c (100 U/ml) for 12 hours, followed by determination of luciferase activity. Bar graphs
represent the mean 6 SEM of three independent experiments (**p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0087377.g007
Figure 8. GAS promoter activity, STAT1 activation and IRF1 expression were reduced in MC2 as compared to VC5. (A) VC5 and (B)
MC2 were cultured in E2-depleted media and transfected with 8 X GAS binding sequence construct, then treated with vehicle (ethanol), E2 (10
29 M)
and stimulated or not with IFN-c (100 U/ml) for 6 hours. Firefly luciferase activities in samples were normalized to Renilla luciferase activities in the
same samples and expressed as fold induction over the un-stimulated mock. Error bars represent the mean6 SEM of three independent experiments
(*p,0.05, ** p,0.01). (C) VC5 and MC2 were stimulated with IFN-c (100 U/ml) for 15 minutes, STAT1 activation was detected using STAT1 Phospho-
Tyrosine701 and Phospho-Serine 727 antibodies. (D) VC5 and MC2 were treated or not with E2 (10
29 M) for 4 hours, followed by stimulation with IFN-c
(100 U/ml) for 15 minutes, STAT1 activation was detected using STAT1 Phospho-Tyrosine701. (E) Western blot analysis of whole cell lysates, prepared
from VC5 and MC2 stimulated with IFN-c (100 U/ml) for 96 hours, for IRF1 (BD-20) expression. Error bars represent the mean 6 SEM of three
independent experiments (*p,0.05, *** p,0.001).
doi:10.1371/journal.pone.0087377.g008
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Figure 9. E2 differentially down regulates IFN-c signaling and IFN-c induced proteins in endogenous ER
+ breast cancer cell lines. (A)
MCF-7, (B) BT-474, (C) T47D, (G) MDA-MD-231, and (H) SK-BR-3 were cultured in E2-depleted media, transfected with 8 X GAS binding sequence
construct, then treated with vehicle (ethanol), E2 (10
29 M) and stimulated or not with IFN-c (100 U/ml) for 6 hours. Firefly luciferase activities in
samples were normalized to Renilla luciferase activities in the same samples and expressed as fold induction over the un-stimulated mock. (D) MCF-7,
(E) BT-474, (F) T47D, (I) MDA-MB-231 and (J) SK-BR-3 were cultured in E2-depleted media, treated with vehicle (ethanol), or E2 (10
29 M) and stimulated
or not with IFN-c (100 U/ml) for 96 hours. Western blot analysis of cytoplasmic extracts was performed for expression of IFN-c inducible proteins:
STAT1 (06-501), IRF1 (BD-20), IRF9 (C-20), GILT (T-18). Each figure represents one of three independent experiments.
doi:10.1371/journal.pone.0087377.g009
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ERa as a suppressor of CIITA pIV activation. Although
mutagenesis of these sites did not reverse the inhibitory effect of
ERa or E2-activated ERa on CIITA pIV activity (Figure 7B), the
experiments do not completely exclude direct ERa suppression of
CIITA activity as there may be other unidentified ERE sites in
either the proximal or distal region of CIITA pIV through which
this effect is mediated. Alternatively, ERa may indirectly suppress
CIITA pIV activation through interacting with another factor
such as AP1 or NFKb that may bind CIITA pIV [21], or by
interacting with factors such as CREB, SRC-1 and CBP/p300
[59] that interact with the regulatory elements of CIITA pIV and
HLA-II promoters [23,60,61]. This remains to be further studied.
Although others have shown an E2 inhibitory effect on MHC
class II expression [17,19,44,45], the described mechanisms were
not CIITA dependent. Tzortzakaki et al (2003) reported E2-
inhibition of IFN-c inducible HLA-DR in both MCF-7 and
T47D, whereby the mechanism involved sequestering the steroid
receptor co-activator 1 (SRC-1) away from the HLA-DRA
promoter by the E2-activated ER [17]. Our study did not assess
cofactors, but similarly, we found E2-inhibition of DR expression
and DRA promoter activity with only slightly reduced CIITA in
MCF-7 (Figure 1 and data not shown). However, our results for
T47D conflict with theirs, as we found no E2 inhibition of HLA-
DR in this cell line. This could be due to differences in the
amounts of E2, as their study used 3–4 log fold more than ours.
Higher than physiological concentrations of E2 were also used to
show an E2 inhibitory effect on murine MHC-II that did not
involve reduced CIITA[45]. Here the E2 inhibitory effect was
mediated through reduced association of the histone acetylation
transferase, CBP, with the MHC-II promoter. Since CBP is
required for acetylation of histones 3 and 4 in the MHC-II
promoter, this resulted in decreased transcription of MHC-II.
Intriguingly, the cell lines in this study expressed both ER
subtypes, which bound to the MHC I-Eb promoter, but as neither
ICI nor tamoxifen reversed the E2 inhibitory effect on MHC-II
promoter, they concluded the mechanism was ER-independent.
Subsequently, they showed the E2 inhibitory effect on CBP was
mediated through E2 activation of JNK MAPK pathway [45].
Although these studies are not directly comparable to ours, they do
suggest additional factors may have contributed to E2-inhibition of
HLA-DR. However, the underlying mechanisms for E2-ERa
inhibition of CIITA transactivation and STAT1 signaling in breast
cancer are likely to be more diverse and complex.
Studies investigating deficient CIITA and MHC class II
expression in various cancer cell lines have identified epigenetic
modifications that result in transcriptional silencing [61,62]. These
include histone deacetylation of the CIITA pIV in squamous cell
carcinomas [63] and rhabdomyosarcomas [64], and hypermethy-
lation of the CpG islands in CIITA pIV colon and gastric
carcinoma lines. Hypermethylation and recruitment of dysregu-
lated methyltransferases were hypothesized as mechanisms for
defective CIITA and HLA-II expression in metastatic breast
cancer [65,66], but these studies were based on a presumed breast
cancer cell line MDA-MB-435. This cell line and its metastatic
variants have a controversial history [67], as there is strong
evidence that they originated from a melanoma cell line [68].
However, it is conceivable that epigenetic modifications are
implicated in the E2-liganded ERa deleterious effect on CIITA
pIV, as numerous epigenetic modifications have been described in
breast cancer that include silencing of ERa in the MDA-MB-231
cell line and downregulation of tumor suppressor genes [69–73].
In our study the E2 mediated downregulation of CIITA pIV
and HLA-II expression in the ERa+ BCCL appears likely due to
aberrant STAT1 signaling with reduced expression of IRF1 or
reduced ability to bind the CIITA promoter. Others have shown
that STAT1 and IRF1 are aberrantly expressed in some ER+
breast cancer tissues and cell lines [74–77] and both have tumor
suppressor properties. Chan et al (2012) reported significantly
decreased STAT1 in human neoplastic tissue of ER+ breast
tumors and showed that knocking out STAT1 in a mouse model
correlated with the development of ER+PR+ luminal A adeno-
carcinoma [77]. Intriguingly, the reduced phosphorylation of
STAT1 and reduced levels of total STAT1 in MC2, compared to
VC5 (Figure 8C), whether treated or not with E2 (Figure 8D)
implies that ERa somehow negatively regulates STAT1 activation
and signaling. We speculate this could occur via direct interaction
of ERa with STAT1, possibly interfering with dimerization and
nuclear translocation or indirectly by interfering with STAT1
promoter activation. Whatever the mechanism, aberrant STAT1
signaling is likely to result in reduced IRF1 levels and subsequently
reduced CIITA activation. However, as ICI treatment of MC2 did
not substantially increase STAT1 levels (data not shown), nor
completely degrade ERa, more studies are required to test this
concept.
A potential explanation for the dramatic reduction of CIITA
pIV activity in MC2 is decreased IRF1 (Figure 8D), which is
essential for IFN-c inducible CIITA transcriptional activation and
HLA-II expression [50,78,79]. Furthermore, E2 diminished IRF1
in MCF-7 and dramatically reduced its expression in BT-474, a
cell line that expresses insignificant amounts of HLA-DR in the
presence and absence of E2 (Figures 1 & 9). In contrast, ERa
2
lines appear to have an intact IFN-c signaling pathway that is not
inhibited by E2. We did not investigate mechanisms underlying
E2-mediated increase in GAS and STAT1 activity, but others have
shown a dependency on SRC kinase activity [80]. Furthermore,
E2 also activates other pathways such as MAPK and PI3K
pathways that interact with the JAK-STAT1 pathway [40,81,82].
In conclusion, our results show that HLA-II expression is
regulated differently by estrogen in ER2 and ER+ breast cancer
cells. To our knowledge this report is the first to show that
activation of ERa by its ligand E2, results in downregulation of
CIITA pIV activity. Although the mechanism is not fully
elucidated, the data suggest that the dysregulation occurs at the
level of STAT1 activation. Such a mechanism would explain the
HLA-DR negative tumor cells in breast carcinomas despite
infiltrating T-cells and high levels of IFN-c and has further
implications for tumor immune escape.
Materials and Methods
Cells
Breast cancer cell lines, obtained from ATCC, included: ERa+
(MCF-7, T47D, and BT-474) and ERa2 (SK-BR-3, MDA-MB-
231 (MDA-231). Cells were grown in Iscove’s Modified Dulbecco’s
Medium (IMDM) (Gibco) supplemented with 10% heat inactivat-
ed fetal bovine serum (FBS) (Gibco), 2 mM L-glutamine,
antibiotic-antimycotic mixture (100 units/ml penicillin G sodium,
100 mg/ml streptomycin sulfate, and 0.25 mg/ml amphotericin B
as FungizoneH), all from Invitrogen. MDA-MB-231 clone 10A and
two stably-transfected lines, MC2 (MDA-MB-231 clone 10A
transfected with ESR1 (NM_000125) and VC5 (MDA-MB-231
clone 10A transfected with an empty vector) were generous gifts
from Dr. Craig Jordan. Cells were grown in phenol red free
minimum essential medium (MEM) (Invitrogen) supplemented
with 5% charcoal/dextran heat inactivated FBS (CD FBS)
(Hyclone), MEM non-essential amino acids, 6 ng/ml recombinant
human insulin, 2 mM L-glutamine and antibiotic-antimycotic
mixture (all from Invitrogen). MC2 and VC5 were maintained
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under selective conditions with G418, 5 mg/ml (Sigma). For
experiments cell lines were detached with 0.25% trypsin (Invitro-
gen) and plated at 36105 cells/well in 6-well plates or
26104 cells/well in 96-well plates. After 24 hours medium was
replaced with fresh medium containing 1029 M E2 and/or
1026 M ICI (Sigma) or vehicle control (ethanol) and left un-
stimulated or stimulated with IFN-c, 100 units/ml (BD Biosci-
ences) for the indicated times depending on the experiment.
Antibodies
Expression of HLA-II and CIITA was determined as follows:
HLA-DR conformers, clone L243 [83] ATCC, purified IgG2a
from supernatant diluted to 2.4 mg/ml for flow cytometry (FC) or
10 ng/ml for Western blot analysis; HLA-DRa, mouse IgG1
(clone Tal 1B5, Abcam, 40 ng/ml, IB); Ii, mouse IgG1 (clone
LN2, BD Biosciences, 5 mg/ml, FC or 200 ng/ml, IB); HLA-DM,
mouse IgG1 (clone MaP.DM1, BD Biosciences, 10 mg/ml, FC
and clone TAL18.1, Abcam, 40 ng/ml, IB); CIITA (rabbit
antiserum # 21, diluted 1/4000), prepared in Dr. Viktor Steimle’s
laboratory [84]. Other antibodies used for Western blotting
included anti-ERa, rabbit IgG (HC-20, Santa Cruz Biotechnol-
ogy, 500 ng/ml); STAT1, rabbit IgG (06-501, Upstate Biotech-
nology, 200 ng/ml); STAT1 Phospho-Tyrosine701 and Phospho-
Serine 727, both rabbit IgG (GenScript, 500 ng/ml); ISGF-3c p48
(IRF9), rabbit IgG (C-20, Santa Cruz Biotechnology, 400 ng/ml);
IRF1, mouse IgG1 (clone BD-20, BD Biosciences, 125 ng/ml);
GILT, goat polyclonal IgG (T-18, Santa Cruz Biotechnology,
250 ng/ml). Isotype-matched nonspecific monoclonal antibodies
(mAbs) included: IgG2a (clone NSG2a) from a local source and
IgG1 (clone MOPC-21, BD Biosciences). Housekeeping proteins
were detected with anti-GAPDH, mouse IgG1 (clone 6C5,
Abcam, 1 ng/ml); a-tubulin, mouse IgG1 (clone B-7, Santa Cruz
Biotechnology, 250 ng/ml) and anti-nuclear matrix protein p84,
mouse IgG2b (clone 5E10, Abcam, 1 mg/ml). Horse Radish
Peroxidase (HRP)-conjugated affiniPure F(ab)2 fragment goat anti-
mouse (GAM) IgG, Fc specific and HRP-conjugated affiniPure
F(ab)2 fragment goat anti-rabbit (GAR) IgG, Fc specific antibodies,
were purchased from Jackson Immunoresearch and HRP
conjugated donkey anti-goat (DAG) antibody IgG, was purchased
from Santa Cruz Biotechnology.
Flow cytometry
Flow cytometry was performed as previously described [85].
Briefly, trypsin-harvested cells, 26105 cells/tube, were incubated
with 25 ml of appropriate mAbs in wash buffer (0.2% CDFCS,
0.02% NaN3 in PBS) for 30 minutes at 4uC. Antibody binding was
detected with phycoerythrin (PE) labeled goat anti-mouse (GAM)
conjugate (Jackson Immunoresearch), followed by fixation in 1.0%
paraformaldehyde (PFA) and analyzed using a FACS Calibur flow
cytometer (Becton-Dickinson). For intracellular staining, the cells
were fixed in 2% PFA and permeabilized with 0.2% Tween 20 in
PBS (Sigma) prior to adding primary antibodies, diluted in wash
buffer containing 0.2% Tween 20 and 0.5% BSA.
Western Blotting
Nuclear and cytoplasmic extracts were prepared using Nuclear
Extract Kit (ActiveMotif) according to the manufacture’s protocol.
Whole cell lysates (WCL) were prepared in either Triton X-100
buffer (PBS pH 7.4,Triton X-100 1%, 0.5 M ethylene-diaminete-
traaccetic acid) or RIPA buffer (PBS, pH7.4, 1% NP40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing
protease inhibitors aprotinin (1 mg/ml), leupeptin (1 mg/ml),
pepstatin A (1 mg/ml) and phenylmethylsulfonyl fluoride
(10 mg/ml). Proteins, quantified using a BCA protein assay kit
(Thermo-Fisher Scientific), were reduced with 2-mercaptoethanol
and electrophoresed (10 mg/lane) using 8–10% SDS PAGE,
followed by western blotting. Membranes, treated with blocking
buffer (5% milk powder in TBS-Tween (0.15 M NaCl, 0.05 M
Tris pH 7.4, 0.05% Tween 20) for 1 hour, were incubated
overnight with primary antibodies at 4uC. Antibody binding was
detected with appropriate HRP-conjugated secondary antibodies
and Immobilon Western Chemiluminescent HRP substrate
(Millipore). Immunoreactivity was visualized and quantified by
scanning densitometry using ImageQuant LAS 4000 and Im-
ageQuant TL8.1 software, respectively (GE Healthcare).
Real-time RT-PCR
Total RNA, extracted using TRIzol Reagent (Invitrogen) and
treated with AmbionH TURBOTM DNase to remove contami-
nating DNA, was quantified using NanoDrop (Thermo Scientific).
The High Capacity cDNA Reverse Transcription kit (Applied
Biosystems) was used for cDNA synthesis according to the
manufacturer’s protocol. Real time PCR was performed using
TaqManH Probe-Based Gene Expression Analysis kit for CIITA
(Hs00172106_m1) and GAPDH (Hs99999905_m1) following the
manufacturer’s recommendations. Quantification was performed
by the comparative threshold cycle (DDCT) method and normal-
ized to GAPDH using StepOnePlusTM (Applied Biosystems). A
control sample without RNA and a reference sample (RAJI, B cell
line) were included in each experiment.
siRNA Transfection
Cells, plated in a 6-well plate at 36105 cells/well for 24 hours,
were transfected with either 25 nM ON-TARGET plus SMART
pool siRNA for ESR1 or non-targeting siRNA (Dharmacon, USA)
using 4 ml DharmaFECT4 transfection reagent (Dharmacon,
USA) per well according to the manufacturer’s protocol. Forty-
eight hours later, the cells were treated with E2 10
29 M or vehicle
control (ethanol) and stimulated with IFN-c, 100 units/ml, for 4 or
24 hours for mRNA and protein expression, respectively.
Reporter gene assays
The CIITA promoter IV firefly luciferase construct [79] and the
8 X GAS firefly luciferase construct [86] were kind gifts from Dr.
Jenny Ting and Dr. Eleanor N. Fish, respectively. Transfection
conditions were optimized using Fugene HD (Roche) transfection
reagent according to the manufacturer’s protocol: briefly a master
mix was prepared by diluting the appropriate plasmid with Opti-
MEM (Gibco) to a concentration of 0.02 mg/ml; Fugene HD was
added to the same mixture in the ratio of 7:2 (Fugene HD in
ml:Plasmid DNA in mg) and left for 20 minutes at ambient
temperature. Cells, plated in a 96-well plate at 26104 cells/well
for 24 hours, at 37uC were transfected with 5 ml of this mixture
and incubated for an additional 24 hours. The medium was then
replaced with medium containing the appropriate treatments and
incubated for 12 hours for CIITA pIV or 6 hours for 8 X GAS
constructs. Transfection efficiency was estimated by co-transfect-
ing the cells with SV-40 Renilla luciferase or green fluorescent
protein (GFP). Luciferase activity was measured using the dual
luciferase assay system (Promega) and a 96-well luminometer
(Fluoroskan Ascent Fl, Labsystems).
Generation of CIITA pIV deletion constructs
Different sets of deletion mutants of P-346/+50 CIITA pIV
were generated by site-directed mutagenesis using QuikChange
Lightning Site-Directed Mutagenesis Kit (Stratagene) according to
the manufacturer’s instructions. Mutagen primers (Table 1) were
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designed with Agilent’s web-based QuikChange Primer Design
Program Sequences. Sequences, deleted from the original
template, are bolded and underlined. All deletions were confirmed
by sequencing.
Statistics
Statistical analysis was performed using Microsoft excel 2010
software. One-way analysis of variance (ANOVA) and Tukey post
hoc tests were used for comparisons within a group. The student t-
test was used for comparing two different treatments for one cell.
All tests were two-sided and p,0.05 was considered significant.
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